Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report the long-term effect of intravitreal bevacizumab on serous macular detachment (SMD) in central retinal vein occlusion (CRVO).

Methods

Retrospective, interventional, noncomparative case series. Nineteen consecutive patients (19 eyes) with SMD secondary to CRVO were included. Primary outcomes were the change of the best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) at final visit. Secondary outcome was the resolution of the SMD.

Results

The mean patient age was 65.6 years, and the mean follow-up time 21.6 months. Of the 19 eyes, 15 eyes were non-ischemic. The average number of bevacizumab injections was 5.9 from baseline to the final visit. Mean logMAR BCVA improved from 1.20 ± 0.45 (20/317) to \( 0.{9}0\pm 0.{54}\left( {{2}0/{16}0} \right){\hbox{ P}} = 0.00{3} \) and mean CFT decreased from 918 ± 280 μm to \( {432}\pm {\hbox{281 P}} = 0.000{1} \) at the final visit. The SMD resolved in 16 of the 19 eyes completely. No local or systemic complication was observed.

Conclusion

In this retrospective case series, a significant improvement of the vision and resolution of the SMD was found after bevacizumab treatment for CRVO with SMD. Large case series are necessary to evaluate the role of the intravitreal bevacizumab treatment for CRVO associated with SMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124:726–732

    Article  PubMed  Google Scholar 

  2. Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491

    Google Scholar 

  3. The Central Vein Occlusion Study Group (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 102:1425–1433

    Google Scholar 

  4. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127:1101–1114

    Article  PubMed  Google Scholar 

  5. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, for the CRUISE Investigators (2010) Ranibizumab for macular edema following central retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133

    Article  PubMed  Google Scholar 

  6. Schatz H, Yannuzzi L, Stransky TJ (1976) Retinal detachment secondary to branch vein occlusion: part I. Ann Ophthalmol 8:1437–1452

    PubMed  CAS  Google Scholar 

  7. Kokame GT, de Leon MD, Tanji T (2001) Serous retinal detachment and cystoid macular edema in hypotony maculopathy. Am J Ophthalmol 131:384–386

    Article  PubMed  CAS  Google Scholar 

  8. Spaide RF, Goldbaum M, Wong DW, Tang KC, Iida T (2003) Serous detachment of the retina. Retina 23:820–846

    Article  PubMed  Google Scholar 

  9. Lerche RC, Schaudig U, Scholz F, Walter A, Richard G (2001) Structural changes of the retina in retinal vein occlusion--imaging and quantification with optical coherence tomography. Ophthalmic Surg Lasers 32:272–280

    PubMed  CAS  Google Scholar 

  10. Spaide RF, Lee JK, Klancnik JK, Gross NE (2003) Optical coherence tomography of branch retinal vein occlusion. Retina 23:343–347

    Article  PubMed  Google Scholar 

  11. Ozdemir H, Karacorlu M, Karacorlu S (2005) Serous macular detachment in central retinal vein occlusion. Retina 25:561–563

    Article  PubMed  Google Scholar 

  12. Yamaguchi Y, Otani T, Kishi S (2006) Serous macular detachment in branch retinal vein occlusion. Retina 26:1029–1033

    Article  PubMed  Google Scholar 

  13. Tsujikawa A, Sakamoto A, Ota M, Kotera Y, Oh H, Miyamoto K, Kita M, Yoshimura N (2010) Serous retinal detachment associated with retinal vein occlusion. Am J Ophthalmol 149:291–301

    Article  PubMed  Google Scholar 

  14. Karacorlu M, Karacorlu SA, Ozdemir H, Senturk F (2007) Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central retinal vein occlusion. Retina 27:1026–1030

    Article  PubMed  Google Scholar 

  15. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339

    PubMed  Google Scholar 

  16. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284

    Article  PubMed  Google Scholar 

  17. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG (2008) Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina 28:1325–1337

    Article  PubMed  Google Scholar 

  18. Beutel J, Ziemssen F, Lüke M, Partsch M, Bartz-Schmidt KU, Bevacizumab Study Group, Gelisken F (2010) Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int Ophthalmol 30:15–22

    Article  PubMed  Google Scholar 

  19. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R (2009) Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147:298–306

    Article  PubMed  CAS  Google Scholar 

  20. Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM, Pegaptanib in Central Retinal Vein Occlusion Study Group (2009) Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127:374–380

    Article  PubMed  CAS  Google Scholar 

  21. Karacorlu M, Ozdemir H, Karacorlu SA (2005) Resolution of serous macular detachment after intravitreal triamcinolone acetonide treatment of patients with branch retinal vein occlusion. Retina 25:856–860

    Article  PubMed  Google Scholar 

  22. Shukla D, Shukla D, Behera UC, Chakraborty S, Mahalakshmi R, Prasad NM (2009) Serous macular detachment as a predictor of resolution of macular edema with intravitreal triamcinolone injection. Ophthalmic Surg Lasers Imaging 40:115–119

    Article  PubMed  Google Scholar 

  23. Ota M, Tsujikawa A, Kita M, Miyamoto K, Sakamoto A, Yamaike N, Kotera Y, Yoshimura N (2008) Integrity of foveal photoreceptor layer in central retinal vein occlusion. Retina 28:1502–1508

    Article  PubMed  Google Scholar 

  24. Guthoff R, Meigen T, Hennemann K, Schrader W (2009) Comparison of Bevacizumab and Triamcinolone for treatment of macular edema secondary to central retinal vein occlusion - a matched-pairs analysis. Ophthalmologica 224:126–132

    Article  PubMed  Google Scholar 

  25. Tao Y, Hou J, Jiang YR, Li XX, Jonas JB (2010) Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye 24:810–815

    Article  PubMed  CAS  Google Scholar 

  26. Wu WC, Cheng KC, Wu HJ (2009) Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 23(4):849–857

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Yüzüncü Yil, Van, Turkey

    Adnan Cinal

  2. Center for Ophthalmology, University of Tübingen, Schleichstr. 12, 72076, Tübingen, Germany

    Adnan Cinal, Focke Ziemssen, Karl U. Bartz-Schmidt & Faik Gelisken

Authors
  1. Adnan Cinal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Focke Ziemssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karl U. Bartz-Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Faik Gelisken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faik Gelisken.

Additional information

Adnan Cinal and Focke Ziemssen contributed equally to this manuscript.

Conflict of interest

The authors have no financial interest related to the manuscript. The authors have full control of all primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cinal, A., Ziemssen, F., Bartz-Schmidt, K.U. et al. Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 249, 513–520 (2011). https://doi.org/10.1007/s00417-010-1551-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1551-2

Keywords

Search

Navigation